Table 3.
Autoantibodies | Females | Males | ||||
---|---|---|---|---|---|---|
RA patients (n = 56) | Control group (n = 56) | P | RA patients (n = 34) | Control group (n = 34) | P | |
aPL |
32.1% (18/56) |
8.9% (5/56) |
.004 |
41.2% (14/34) |
14.7% (5/34) |
.02 |
aCL |
16.1% (9/56) |
5.3% (3/56) |
NS |
14.7% (5/34) |
5.9% (2/34) |
NS |
aβ2GPI |
30.3% (17/56) |
8.9% (5/56) |
.007 |
35.3% (12/34) |
11.8% (4/34) |
.04 |
aβ2GPI‐IgA |
23.2% (13/56) |
7.1% (4/56) |
.03 |
32.3% (11/34) |
8.8% (3/34) |
.03 |